CTA Protein Array
Profiling against cancer antigens. Using the CTA Protein Array, Sengenics can quantify autoantibodies against more than 200 clinically relevant cancer testis antigens. These are tumor antigens normally expressed in germ cells but not in adult somatic tissues. In cancers, this regulation can be disrupted, resulting in CTA expression in tumors. The CTA array is ideal for research related to cancer immunotherapy.
Receive your quote directly from the manufacturer.
Using the CTA Protein Array, Sengenics can quantify autoantibodies against more than 200 clinically relevant cancer testis antigens. These are tumor antigens normally expressed in germ cells but not in adult somatic tissues. In cancers, this regulation can be disrupted, resulting in CTA expression in tumors. The CTA array is ideal for research related to cancer immunotherapy.
Autoantibodies: The key to early diagnosis and improved patient stratification
Sengenics CSO and inventor of the KREX™ protein folding technology, Professor Jonathan Blackburn, discusses the applications of KREX™ for the discovery of autoantibody-based companion diagnostics and early disease detection biomarkers, as well as the potential benefits in the treatment of autoimmune disease, cancer, neurological and infectious diseases and beyond
